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Abstract 
Purpose: To investigate the effect of pinoresinol diglucoside (PDG) on dexamethasone-induced 
osteoporosis in rats. 
Methods: Sixty Wistar rats were randomly and equally divided into normal, control, alendronate and 
PDG (10, 20 or 40 mg/kg) groups. Bone tissue parameters, including length, transverse diameter, 
weight, bone mineral content (BMC) and bone mineral density (BMD), were determined using vernier 
caliper, electronic balance and single photon bone mineral density meter. Serum biochemical indices, 
including Ca2+, inorganic phosphorus (IP), IL-6, TNF-α and alkaline phosphatase (ALP), were 
determined using colorimetry and enzyme-linked immunosorbent assay (ELISA). Osteoprotegerin 
(OPG) and receptor activator of nuclear factor-κB ligand (RANKL) proteins were detected by Western 
blot. 
Results: PDG (10, 20 or 40 mg/kg) increased significantly (p < 0.05 or 0.01) transverse diameter (3.64 
– 3.79 vs. 3.31 mm), weight (0.73 – 0.78 vs. 0.67 g), BMC (0.16 – 0.23 vs. 0.12 g/cm), BMD (0.27 – 
0.35 vs. 0.22 g/cm2) of right femur, serum Ca2+ level (2.16 – 2.39 vs. 1.94 mmol/L), and OPG level of 
left femur, compared with those in the control group. PDG (10, 20 or 40 mg/kg) reduced significantly (p 
< 0.05 or 0.01) serum IP (1.34 – 1.14 vs. 1.76 mmol/L), IL-6 (103.25 – 95.38 vs. 108.74 ng/L), TNF-α 
(87.46 – 82.05 vs. 92.38 ng/L), ALP (334.79 – 276.32 vs. 486.45 U/L) levels or activities, and RANKL 
level of left femur, compared with those in the control group. 
Conclusion: PDG exhibits a protective effect on dexamethasone-induced osteoporosis by increasing 
bone mass and regulating bone metabolism. Thus, PDG may be a candidate drug for treating 
osteoporosis. 
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Osteoporosis (OP) is a systemic disease of 
skeleton characterized by reduction of bone 
mass and disruption of bone architecture, 
resulting in reduced bone strength and increased 
risk of fragility fractures which represent the key 
clinical symptom of OP [1,2]. Based on etiology, 
OP is divided into 3 types: primary, secondary 
and idiopathic OP. Secondary OP is induced by 
some drugs and diseases, such as 
glucocorticoids and lupus erythematosus [3,4]. 
 
Glucocorticoids, a class of steroid hormones, are 
secreted by zona fasciculate of adrenal cortex. 
Physiological doses of glucocorticoids can 
regulate biosynthesis and metabolism of sugar, 
fat and protein [5]. Supra-physiological doses of 
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glucocorticoids exhibit anti-immune, anti-shock 
and anti-inflammatory activities, and therefore, 
glucocorticoids are widely used to treat 
anaphylactic disease, inflammation, severe 
infection, etc [6]. However, long-term excessive 
use of glucocorticoids will induce bone 
disruption, especially OP. Nowadays, 
glucocorticoids-induced OP is the most common 
secondary OP [7]. 
 
At present, it is the research focus to find safe 
and effective drugs for preventing and treating 
glucocorticoids-induced OP. Du-Zhong 
(Eucommia ulmoides Oliv.) can be used to 
prevent ovariectomy-induced OP in rats and 
disuse-induced OP in hind limb suspension rats 
[8,9]. Pinoresinol diglucoside (PDG, Figure 1) is 
a main constituent of Du-Zhong [10], but its effect 
on OP remains unknown. Therefore, this work 
was designed to investigate the effect of PDG on 
dexamethasone (DEX, a kind of glucocorticoid)-




Figure 1: Chemical structure of pinoresinol 




Chemicals and reagents 
 
DEX injection was provided by Henan Runhong 
Pharmaceutical Co., Ltd. (Zhengzhou, China). 
Alendronate was purchased from Wante 
Pharmaceutical Co., Ltd. (Haikou, China). PDG 
(purity ≥ 98 %) was purchased from Sigma-
Aldrich (Shanghai, China). Ca2+, inorganic 
phosphorus (IP) and alkaline phosphatase (ALP) 
assay kits were purchased from Nanjing 
Jiancheng Bioengineering Institue (Nanjing, 
China). IL-6 and TNF-α ELISA kits were obtained 
from Neobioscience (Shanghai, China). 
Enhanced BCA protein assay kit was purchased 
from Beyotime (Haimen, China). Primary 
antibodies for β-actin, osteoprotegerin (OPG) 
and receptor activator of nuclear factor-κB ligand 
(RANKL), along with horse radish peroxidase 
(HRP)-conjugated anti-rabbit antibody were 
purchased from Cell Signaling Technology 
(Beverly, MA, USA) and Abcam (Cambridge, 
UK). Enhanced chemiluminescence detection kit 
for HRP was provided by Biological Industries 




Wistar female rats (180 ± 20 g) were provided by 
Laboratory Animal Centre, Huzhou Institute for 
Food and Drug Control and were housed in a 
temperature controlled vivarium (25 °C) with 
relative humidity of 65 % and 12/12-h light-dark 
cycle. All rats have free access to water and 
food. All animal treatments were conducted in 
strict accordance with the National Institutes of 
Health Guide for Care and Use of Laboratory 
Animals [11]. This study was performed with the 
approval of the ethics committee of Laboratory 
Animal Centre, Huzhou Institute for Food and 





Sixty Wistar rats were randomly and averagely 
divided into normal, control, alendronate and 
PDG (10, 20 or 40 mg/kg) groups. After fasting 
for 12 h, rats in the control, alendronate or PDG 
(10, 20 or 40 mg/kg) groups were administrated 
orally with normal saline, 1 mg/kg alendronate, 
10 mg/kg PDG, 20 mg/kg PDG or 40 mg/kg PDG 
at 9:00 a.m. once a day for 8 weeks, respectively 
and injected intramuscularly with 2.5 mg/kg DEX 
at 6:00 p.m. twice a week for 8 weeks to 
establish OP model. Rats in the normal group 
were administrated orally with normal saline at 
9:00 a.m. once a day for 8 weeks and injected 
intramuscularly with normal saline at 6:00 p.m. 
twice a week for 8 weeks. Different amounts of 
alendronate or PDG were dissolved in normal 
saline to get different concentrations such that 
each rat received an intragastric volume of 20 
mL/kg. Body weight of rats in all groups was 
weighed using electronic balance once a week 
for 8 weeks. 
 
After being deeply narcotized with 10 % chloral 
hydrate at a dose of 3.0 mL/kg by intraperitoneal 
injection on 57th day, the abdominal aortic blood 
of each rat was collected and centrifuged at 3000 
rpm for 10 min at 4 °C to obtain serum, which 
was stored at -20 °C for further analysis. Then 
the left and right femurs of each rat were rapidly 
separated and were flushed with normal saline to 
remove residual blood. All clean femurs were 
stored at -80 °C for further analysis. 
 
Determination of bone tissue parameters 
 
Length and transverse diameter of right femur 
were measured by vernier caliper. Weight of right 
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femur was weighed using electronic balance. 
Bone mineral content (BMC) and bone mineral 
density (BMD) of right femur were determined 
using a BH41-HH6005 single photon bone 
mineral density meter (Beijing Zhongxi Yuanda 
Science and Technology Co., Ltd., China). 
 
Determination of serum biochemical indices 
 
Serum Ca2+, IP, IL-6, TNF-α and ALP levels or 
activities were determined using corresponding 
kits according to the manufactures’ instruction for 
each. After reactions were completed, 
absorbance of each index in each sample was 
determined using a Thermo Scientific Microplate 
Reader (Waltham, MA, USA). The absorbance 
for each index was used to calculate the activity 
or level based on the corresponding standard 
curves. 
 
Detection of OPG and RANKL proteins 
 
OPG and RANKL levels in left femur were 
detected by Western blot. After pretreatment with 
lysis buffer, grinding and centrifugation at 12000 
rpm for 10 min at 4 ºC, total protein of left femur 
tissue was extracted, and its concentration was 
determined using enhanced BCA protein assay 
kit. Then equal amounts of total protein (about 40 
μg) were separated by 10 % sodium dodecyl 
sulfate/polyacrylamide and blotted on PVDF 
membrane. After blocking with 5 % non-fat milk, 
PVDF membranes were incubated with primary 
antibodies for β-actin, OPG and RANKL 
overnight at 4 ºC. After washing with Tris 
buffered saline-Tween (TBS-T), PVDF 
membranes were incubated with HRP-
conjugated anti-rabbit antibody in TBS-T at room 
temperature for 2 h. Then, the PVDF membranes 
were washed with TBS-T, and proteins were 
detected by chemiluminescence with the aid of 
enhanced chemiluminescence detection kit for 
HRP. β-actin was used to assess equal protein 
loading, and proteins levels were represented as 




All data are presented as mean ± standard 
deviation (SD). One-way ANOVA was used to 
analyze differences among different groups with 
the aid of SPSS 21.0 (IBM SPSS Statistics, 
USA). Differences were considered statistically 




Effect of drug administration on rat body 
weight 
 
As shown in Figure 2, body weight of rats in all 
groups was gradually increased during the 
experimental period, and there were no 
significant differences among body weight of rats 
in different groups. These results suggested that 
body weight gain of rats was not affected 
significantly by drug administration, such as 
normal saline, alendronate, DEX and PDG. 
 
Effect of PDG on bone tissue parameters 
 
As shown in Table 1, the transverse diameter, 
weight, BMC and BMD of right femur in the 
control group were decreased significantly (p < 
0.01) relative to those in the normal group. After 
treatment with alendronate (1 mg/kg) or PDG 
(10, 20, or 40 mg/kg), the transverse diameter, 
weight, BMC and BMD of right femur in rats with 
OP were increased significantly (p < 0.05 or 
0.01), compared with those in the control group. 
Length of right femur was not affected 
significantly by drugs administration. 
 
 
Figure 2: Effect of drug administration on rat body weight 
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Table 1: Effect of PDG on length, transverse diameter, weight, BMC and BMD of right femur in rats with OP 
 









Normal 32.81 ± 1.98 3.87 ± 0.32 0.81 ± 0.10 0.26 ± 0.06 0.36 ± 0.05 
control 31.48 ± 1.76 3.31 ± 0.26## 0.67 ± 0.05## 0.12 ± 0.03## 0.22 ± 0.03## 
Alendronate 32.57 ± 1.62 3.75 ± 0.25** 0.76 ± 0.06** 0.24 ± 0.05** 0.34 ± 0.06** 
10 mg/kg PDG 31.98 ± 1.56 3.64 ± 0.19** 0.73 ± 0.07* 0.16 ± 0.04* 0.27 ± 0.04** 
20 mg/kg PDG 32.72 ± 1.74 3.68 ± 0.22** 0.75 ± 0.06** 0.18 ± 0.05** 0.31 ± 0.05** 
40 mg/kg PDG 32.54 ± 1.93 3.79 ± 0.23** 0.78 ± 0.08** 0.23 ± 0.05** 0.35 ± 0.05** 
##P < 0.01, compared with those in the normal group; *p < 0.05, **p < 0.01, compared with those in the control 
group 
 
Table 2: Effect of PDG on serum Ca2+, IP, IL-6, TNF-α and ALP levels or activities in rats with OP 
 
Group Ca2+ (mmol/L) IP (mmol/L) ALP (U/L) IL-6 (ng/L) TNF-α (ng/L) 
Normal 2.52 ± 0.21 1.12 ± 0.14 226.34 ± 28.64 92.63 ± 3.64 78.63 ± 4.25 
Control 1.94 ± 0.18## 1.76 ± 0.22## 486.45 ± 35.67## 108.74 ± 5.98## 92.38 ± 5.69## 
Alendronate 2.48 ± 0.23** 0.98 ± 0.11** 258.41 ± 27.59** 93.47 ± 3.14** 80.16 ± 3.85** 
10 mg/kg PDG 2.16 ± 0.15** 1.34 ± 0.18** 334.79 ± 31.53** 103.25 ± 4.17* 87.46 ± 4.13* 
20 mg/kg PDG 2.27 ± 0.19** 1.21 ± 0.16** 314.67 ± 30.49** 99.72 ± 3.83** 84.27 ± 3.64** 
40 mg/kg PDG 2.39 ± 0.22** 1.14 ± 0.17** 276.32 ± 29.86** 95.38 ± 3.56** 82.05 ± 3.71** 




Figure 3: Effect of PDG on OPG and RANKL levels of left femur in rats with OP; ##p < 0.01, compared with those 
in the normal group; **p < 0.01, compared with those in the control group 
 
Effect of PDG on serum biochemical indices 
 
As listed in Table 2, serum Ca2+ level in the 
control group was decreased significantly (p < 
0.01) and serum IP, IL-6, TNF-α and ALP levels 
or activities in the control group were increased 
significantly (p < 0.01), compared with those in 
the normal group. After treatment with 
alendronate (1 mg/kg) or PDG (10, 20 or 40 
mg/kg), serum Ca2+ level in rats with OP was 
increased significantly (p < 0.01) and serum IP, 
IL-6, TNF-α and ALP levels or activities in rats 
with OP were decreased significantly (p < 0.05 or 
0.01), compared with those in the control group. 
 
Effect of PDG on OPG and RANKL levels of 
left femur in rats with OP 
 
As shown in Figure 3, the OPG level of left femur 
in the control group was decreased significantly 
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(p < 0.01) and the RANKL level of left femur in 
the control group was increased significantly (p < 
0.01), compared with those in the normal group. 
After treatment with alendronate (1 mg/kg) or 
PDG (10, 20, or 40 mg/kg), the OPG level of left 
femur in rats with OP was increased significantly 
(p < 0.01) and the RANKL level of left femur in 
rats with OP was decreased significantly (p < 




In this work, the protective effects and possible 
mechanisms of PDG against DEX-induced OP in 
rats were investigated for the first time. Body 
weight is a critical and direct index to evaluate 
the effect of drugs on body functions, such as 
gastrointestinal functions and physiological 
metabolism [12]. In the study, the body weight 
gain of rats was not affected by drugs 
administration, suggesting that the results of this 
study were credible and not affected by the 
notable side effect caused by the drugs 
administration. 
 
BMC and BMD are two meaningful indices to 
assess bone quality and are closely related to 
degree of OP [13,14]. Length, transverse 
diameter and weight of right femur can directly 
reflect quality of bone [15]. In the study, the 
transverse diameter, weight, BMC and BMD of 
right femur in the control group were decreased 
relative to those in the normal group, and these 
reductions were reversed by alendronate a 
known drug used to treat OP [16], indicating that 
the OP model and known treatment were 
successfully established and administrated. 
Meanwhile, these reductions were also reversed 
by PDG (10, 20 or 40 mg/kg), suggesting that 
PDG showed protective effect on DEX-induced 
OP by increasing bone mass. 
 
ALP, a phosphomonoesterase, is secreted from 
osteoblast and is widely distributed in various 
kinds of tissues and organs, especially bone and 
liver [17]. ALP activity can reflect differentiated 
degree of osteoblast, used to evaluate bone 
formation ability [18]. Bone consists of bone 
mineral and matrix, and calcium and phosphorus 
are the maximum mineral composition in bone 
matrix. When blood calcium level is low, calcium 
in bone matrix can be released into blood to keep 
normal blood calcium level [19]. Glucocorticoids 
can cause the reduction of blood calcium level by 
inhibiting transmembrane transport and intestinal 
absorption of calcium and increasing excretion of 
calcium [20]. Negative calcium balance can 
compensatorily increase blood phosphorus level 
by promoting the release of phosphorus in bone 
matrix into blood and can further promote the 
release of calcium in bone matrix into blood [21]. 
These glucocorticoids-induced changes can 
increase bone resorption, which compensatorily 
increase ALP activity to promote bone formation 
[22]. The glucocorticoids-induced bone 
resorption and abnormal bone reconstruction 
lead to the occurrence of OP. In the study, the 
DEX-induced reduction of serum Ca2+ level and 
increase of serum IP level and ALP activity were 
reversed by PDG (10, 20 or 40 mg/kg), 
suggesting that PDG showed protective effect on 
DEX-induced OP by regulating bone metabolism. 
IL-6 and TNF-α can increase bone resorption 
and inhibit bone formation by inducing the 
differentiation of osteoclast precursor cell to 
osteoclast, promoting degradation of bone matrix 
and inhibiting activity of osteoblast [23]. The 
results of this study indicated that the DEX-
induced increase of serum IL-6 and TNF-α level 
were reversed by PDG (10, 20 or 40 mg/kg), 
indicating that PDG showed protective effect on 
DEX-induced OP by regulating bone metabolism. 
OPG/RANKL/RANK system plays an interactive 
role in generation of osteoclast and the balance 
between bone resorption and bone formation 
[24]. Combination between RANKL and RNAK 
with tumor necrosis factor receptor related 
factors can promote bone resorption by inducing 
differentiation of osteoclast precursor cell to 
osteoclast. OPG can inhibit the differentiation of 
osteoclast precursor cell to osteoclast by 
competitively inhibiting the combination between 
RANKL and RNAK [25]. In the study, the DEX-
induced reduction of OPG protein level in left 
femur and increase of RANKL protein level in left 
femur were reversed by PDG (10, 20 or 40 
mg/kg), indicating that PDG showed protective 
effect on DEX-induced the unbalance between 




PDG exhibits a protective effect on DEX-induced 
OP in rats by increasing bone mass and 
regulating bone metabolism, which is achieved 
by regulating serum Ca2+, IP, IL-6, TNF-α and 
ALP levels or activities as well as OPG and 
RANKL protein levels in bone tissue. Thus, PDG 
has a potential to be a candidate drug for treating 
OP. This, however, needs to be further 
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